Helix BioPharma Corp., a clinical-stage oncology company, announced today the appointment of Markus Loeffler, MD, MBA, as Chief Medical Officer (CMO). Dr. Loeffler's arrival comes as Helix prepares to enter a more execution-focused phase of clinical development, with multiple programs approaching key regulatory and clinical milestones. As CMO, he will lead the strategy and execution of Helix's clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab in first-line non-small cell lung cancer (NSCLC), while guiding LEUMUNA™ toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix, expressed confidence in the appointment, stating, "I've had the privilege of working with Markus before, and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs. He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare LEUMUNA to enter the clinic."
Dr. Loeffler brings more than three decades of leadership in oncology drug development, having held senior clinical development and CMO roles at leading companies such as Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. He notably led the pivotal Phase III clinical program for Lutathera®, which was subsequently approved for the treatment of certain gastroenteropancreatic neuroendocrine tumors. His extensive experience spans small molecules, biologics, antibody-drug conjugates, radiopharmaceuticals, and immunotherapies, from early clinical development through Phase III and regulatory approval.
In a statement, Dr. Loeffler said, "I'm excited to join Helix at such an important stage in its evolution. The Company's pipeline combines strong scientific foundations with clear clinical development opportunities. I am particularly enthused by the opportunity to advance L-DOS47 in combination with checkpoint inhibition and to bring LEUMUNA toward its first clinical evaluation. I look forward to working alongside the team to translate these programs into meaningful new treatment options for patients with difficult-to-treat cancers."
The timing of this appointment is critical as Helix's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for NSCLC. Additional candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. The company's focus on underserved patient populations with difficult-to-treat cancers underscores the strategic importance of Dr. Loeffler's leadership in navigating the upcoming clinical trials and regulatory interactions.
Dr. Loeffler's proven ability to drive innovative oncology therapies through the development pathway is expected to be a key asset for Helix. His leadership will be instrumental in advancing L-DOS47 into its next stage of clinical development and preparing LEUMUNA to enter the clinic. This appointment aligns with Helix's goal of translating its scientific foundation into viable treatment options for patients with difficult-to-treat cancers.
For more information about Helix BioPharma and its pipeline, visit https://www.helixbiopharma.com/.
